^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Soltamox (tamoxifen citrate)

    Associations

    News

    Trials
    Company:
    Jazz
    Drug class:
    Estrogen receptor modulator
    Related drugs:
    Associations

    News

    Trials
    16d
    Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)
    P2/3, N=260, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)
    20d
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, University of Chicago | Initiation date: Jul 2024 --> Jan 2025
    Trial initiation date • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    4ms
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    5ms
    Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=150 --> 19
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
    6ms
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov)
    P3, N=394, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2024 --> May 2025
    Trial completion date • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Avastin (bevacizumab) • letrozole • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Soltamox (tamoxifen citrate)
    6ms
    MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Nebraska | Initiation date: May 2024 --> Sep 2024
    Trial initiation date
    |
    Soltamox (tamoxifen citrate)
    7ms
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3; Trial completion date: Mar 2024 --> Oct 2032
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    8ms
    The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
    P2, N=30, Completed, Johns Hopkins University | Active, not recruiting --> Completed
    Trial completion
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    letrozole • exemestane • Soltamox (tamoxifen citrate)
    9ms
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, University of Chicago
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    9ms
    MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Nebraska
    New P1 trial
    |
    Soltamox (tamoxifen citrate)
    10ms
    Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> Feb 2025
    Trial completion date • Metastases
    |
    ER (Estrogen receptor) • NCOA3 (Nuclear Receptor Coactivator 3)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
    12ms
    EMPRESS: Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (clinicaltrials.gov)
    P2, N=92, Recruiting, MedSIR
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    giredestrant (GDC-9545) • Soltamox (tamoxifen citrate)
    1year
    ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
    P2, N=38, Completed, Emory University | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    1year
    Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)
    P2/3, N=260, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)
    1year
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Recruiting, Jose Pablo Leone | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    over1year
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2023 --> Jul 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    over1year
    Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2023 --> May 2024
    Trial completion date • Metastases
    |
    ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
    over1year
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Jose Pablo Leone | Initiation date: Feb 2023 --> Oct 2023
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    over1year
    ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Emory University | Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    over1year
    Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2022 --> May 2023
    Trial completion date • Metastases
    |
    ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
    over1year
    Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
    almost2years
    Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Stanford University | N=100 --> 150
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
    almost2years
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3; N=10000 --> 5083 | Trial completion date: Feb 2023 --> Mar 2024
    Trial completion date • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2years
    Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Stanford University | N=264 --> 100
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
    2years
    The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
    P2 | N=30 | Active, not recruiting | Sponsor: Johns Hopkins University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Nov 2023
    Trial completion date • Enrollment closed
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive • PGR expression
    |
    MammaPrint • BluePrint
    |
    letrozole • exemestane • Soltamox (tamoxifen citrate)
    2years
    Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
    P1b; Active, not recruiting --> Terminated; Drug manufacturer decision to terminate development.
    Combination therapy • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    FoundationOne® CDx
    |
    Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
    2years
    Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
    P1b; Recruiting --> Active, not recruiting | N=12 --> 4
    Combination therapy • Enrollment change • Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    FoundationOne® CDx
    |
    Ibrance (palbociclib) • fulvestrant • Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
    2years
    ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    over2years
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Jose Pablo Leone
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    over2years
    Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=264, Not yet recruiting, Stanford University | Initiation date: Mar 2022 --> Jan 2023
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • Truseltiq (infigratinib) • letrozole • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
    almost3years
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3; Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    almost3years
    Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=264, Not yet recruiting, Stanford University | Initiation date: Dec 2021 --> Mar 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • Truseltiq (infigratinib) • letrozole • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
    3years
    Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Emily Marcinkowski
    Clinical • New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    3years
    The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
    P2; Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive • PGR expression
    |
    MammaPrint
    |
    letrozole • exemestane • Soltamox (tamoxifen citrate)
    3years
    Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=264, Not yet recruiting, Stanford University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • Truseltiq (infigratinib) • letrozole • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
    3years
    ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
    P2, N=42, Recruiting, Emory University | Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Jun 2021 --> Aug 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    3years
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    over3years
    Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jan 2022 --> Nov 2020
    Clinical • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
    almost4years
    SOFT: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (clinicaltrials.gov)
    P3, N=3066, Active, not recruiting, International Breast Cancer Study Group | Trial completion date: Dec 2031 --> Dec 2025
    Clinical • Trial completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    exemestane • triptorelin • Soltamox (tamoxifen citrate)
    almost4years
    Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jan 2021 --> Jan 2022
    Clinical • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
    4years
    The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Johns Hopkins University | Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    letrozole • exemestane • Soltamox (tamoxifen citrate)
    4years
    Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
    P1b;Not yet recruiting --> Recruiting
    Combination therapy • Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    FoundationOne® CDx
    |
    Ibrance (palbociclib) • fulvestrant • Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)